Open AccessPhosphomannose Isomerase High Expression Associated with Better Prognosis in Pancreatic Ductal Adenocarcinoma
Author(s) -
Zahra Alipour,
Diana Agostini-Vulaj,
Jennifer Findeis-Hosey,
Lei Liu,
Raúl González,
Michael G. Drage,
Hannah R. Krigman,
Zhongren Zhou
Publication year - 2021
Publication title -
clinical and experimental gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.113
H-Index - 30
ISSN - 1178-7023
DOI - 10.2147/ceg.s316492
Subject(s) - medicine , tissue microarray , pancreatic cancer , immunohistochemistry , adenocarcinoma , pancreatic ductal adenocarcinoma , cancer , pathological , oncology , intensity (physics) , gastroenterology , cancer research , physics , quantum mechanics
Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer-related death in the United States. The need for increased patient survival has not been met for PDAC. The addition of mannose to conventional chemotherapy leads to accumulation of mannose metabolite in cancer cells and increases subsequent cell death. This susceptibility to mannose depends on the levels of phosphomannose isomerase (PMI). The cancer cells with lower levels of PMI are more sensitive to mannose than cells with higher levels. In this study, we investigated the association of PMI expression with clinical and pathological features of PDAC cases.